Reviewing Fentora's Existing RiskMAP
Executive Summary
Risk management has been a part of Cephalon's pain products since their initial approval. Actiq was introduced in 1998 with a plan, the first Schedule II opioid analgesic to have one. When Fentora was approved in 2006, it was introduced with a modernized version of RMPs, the Risk Minimization Action Plan. Over time Cephalon has modified the Fentora RiskMAP, which is traced in the company's briefing material for the advisory panel. The most recent update was in February 2008.
You may also be interested in...
Fentora Expansion Awaits REMS Evaluation
“Complete response” letter calls for Cephalon to “demonstrate” that risk management works before Fentora can add new indication.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials